Stephen Kondash, MD
Ophthalmology · Cincinnati, OHNPI 1962404186
Payments from drug & device makers
Across 178 payments — averaging $30.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$806
- AbbVie$647
- Johnson & Johnson Surgical Vision, Inc.$505
- Sun Pharmaceutical Industries Inc.$340
- Omeros Corporation$282
- Bausch & Lomb Americas Inc.$215
- plus $3K from 23 others
What the payments were for
- Food & beverage$5,484100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 22 | $806 |
| AbbVie(2 entities) | 21 | $647 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $505 |
| Sun Pharmaceutical Industries Inc. | 13 | $340 |
| Omeros Corporation | 24 | $282 |
| Bausch & Lomb Americas Inc. | 5 | $215 |
| Ivantis, Inc | 2 | $212 |
| Ocular Therapeutix, Inc. | 6 | $203 |
| Novartis | 9 | $192 |
| Carl Zeiss Meditec, Inc. | 2 | $178 |
| Aerie Pharmaceuticals, Inc. | 9 | $178 |
| Tarsus Pharmaceuticals, Inc. | 7 | $167 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $166 |
| Rxsight Inc | 2 | $161 |
| Glaukos Corporation | 3 | $158 |
| Amgen(2 entities) | 8 | $141 |
| Harrow Eye, LLC | 6 | $138 |
| Biotissue Holdings Inc. | 1 | $136 |
| Dompe US, Inc. | 1 | $112 |
| Thea Pharma Inc. | 5 | $111 |
| Topcon Healthcare, Inc. | 1 | $86 |
| Rayner Intraocular Lenses Limited | 3 | $84 |
| Sight Sciences, Inc. | 4 | $67 |
| Halozyme Inc | 3 | $55 |
| NEW World Medical,inc. | 2 | $37 |
| Shire North American Group Inc | 2 | $35 |
| Astellas Pharma US Inc | 1 | $31 |
| Akorn, Inc. | 1 | $20 |
| Kala Pharmaceuticals, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$483
- RXSIGHT CONTACT LENS$141
- RXSIGHT INJECTOR CARTRIDGE$141
- RXSIGHT INJECTOR HANDPIECE$141
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$141
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$141
- Prokera$136
- AmnioGraft$136
- OZURDEX$125
- MIEBO$124
- VisuMax$123
- ARTEVO 800$123
- DEXTENZA$121
- Oxervate$112
- iDoseTR$110
- DURYSTA$104
- CEQUA$103
How this compares
$5,484 in reported general payments places this provider in the 80th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 63 | $61,576 |
| XdemvyLotilaner | 20 | $36,678 |
| XiidraLifitegrast | 30 | $29,588 |
| LumiganBimatoprost | 54 | $25,386 |
| Alphagan PBrimonidine Tartrate | 31 | $8,769 |
| Latanoprost | 904 | $8,443 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $5,979 |
| Cyclosporine | 15 | $5,617 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 388 | $4,520 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 38 | $3,992 |
| Brimonidine Tartrate | 131 | $3,933 |
| Timolol Maleate | 213 | $1,951 |
| Prednisolone Acetate | 55 | $1,658 |
| Ketorolac Tromethamine | 109 | $1,598 |
| ValacyclovirValacyclovir Hcl | 17 | $1,207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $647 | $101,709167 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $167 | $36,67820 claims |
| Bausch & Lomb Americas Inc.Xiidra | $215 | $29,58830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Cincinnati
- Daniel MillerCincinnati$2.3M
- Michael SnyderCincinnati$1.3M
- Christopher RiemannCincinnati$985K
- Robert SiskCincinnati$831K
- Anup KhatanaCincinnati$794K
- Robert OsherCincinnati$720K
- Haroon ChaudhryCincinnati$708K
- Christopher DevineCincinnati$623K
- Robert BenzaCincinnati$224K
- Linda GreffCincinnati$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.